Spero Therapeutics, Inc. (SPRO)
1.19
-0.07
(-5.56%)
USD |
NASDAQ |
Oct 02, 16:00
1.195
0.00 (0.00%)
Pre-Market: 20:00
Spero Therapeutics Price : 1.19 for Oct. 2, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 02, 2026 | 1.26 | 1.266 | 1.170 | 1.19 | 906916.0 |
| Oct 01, 2026 | 1.22 | 1.31 | 1.195 | 1.26 | 1.039M |
| Sep 30, 2026 | 1.21 | 1.29 | 1.20 | 1.21 | 558213.0 |
| Sep 29, 2026 | 1.20 | 1.22 | 1.17 | 1.20 | 334908.0 |
| Sep 28, 2026 | 1.22 | 1.22 | 1.175 | 1.19 | 393255.0 |
| Sep 25, 2026 | 1.27 | 1.29 | 1.21 | 1.23 | 542771.0 |
| Sep 24, 2026 | 1.25 | 1.29 | 1.24 | 1.25 | 476932.0 |
| Sep 23, 2026 | 1.36 | 1.398 | 1.24 | 1.26 | 1.403M |
| Sep 22, 2026 | 1.30 | 1.44 | 1.28 | 1.36 | 7.764M |
| Sep 21, 2026 | 1.14 | 1.15 | 1.12 | 1.14 | 319103.0 |
| Sep 18, 2026 | 1.12 | 1.21 | 1.115 | 1.13 | 501372.0 |
| Sep 17, 2026 | 1.14 | 1.14 | 1.114 | 1.12 | 181774.0 |
| Sep 16, 2026 | 1.12 | 1.14 | 1.10 | 1.11 | 439642.0 |
| Sep 15, 2026 | 1.14 | 1.151 | 1.11 | 1.13 | 225284.0 |
| Sep 14, 2026 | 1.13 | 1.16 | 1.13 | 1.14 | 267141.0 |
| Sep 11, 2026 | 1.13 | 1.15 | 1.13 | 1.13 | 310631.0 |
| Sep 10, 2026 | 1.18 | 1.18 | 1.12 | 1.12 | 569285.0 |
| Sep 09, 2026 | 1.20 | 1.21 | 1.17 | 1.17 | 367061.0 |
| Sep 08, 2026 | 1.21 | 1.22 | 1.19 | 1.19 | 348592.0 |
| Sep 04, 2026 | 1.20 | 1.22 | 1.185 | 1.21 | 362984.0 |
| Sep 03, 2026 | 1.22 | 1.23 | 1.201 | 1.22 | 203326.0 |
| Sep 02, 2026 | 1.20 | 1.239 | 1.20 | 1.22 | 169514.0 |
| Sep 01, 2026 | 1.22 | 1.22 | 1.18 | 1.20 | 385398.0 |
| Aug 31, 2026 | 1.20 | 1.23 | 1.20 | 1.22 | 338466.0 |
| Aug 28, 2026 | 1.21 | 1.22 | 1.181 | 1.20 | 312829.0 |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Inovio Pharmaceuticals, Inc. | 1.16 |
| Fortress Biotech, Inc. | 2.03 |
| Kura Oncology, Inc. | 10.65 |
| ACADIA Pharmaceuticals, Inc. | 19.95 |
| Alnylam Pharmaceuticals, Inc. | 219.72 |
Price Related Metrics
| PE Ratio | 10.91 |
| PS Ratio | 1.599 |
| Price to Book Value | 1.565 |
| Price to Free Cash Flow | 3.508 |
| Earnings Yield | 9.17% |
| Market Cap | 69.19M |
| Operating PE Ratio | 26.64 |
| Normalized PE Ratio | 10.21 |